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The molecular pathology of bladder cancer has been the subject of considerable interest and mutation of the p53 gene, which has
been associated with more invasive bladder cancer, has been widely studied. Further, there is evidence that p53 inactivation (either
mutation or protein dysregulation), independent of stage, may be predictive of bladder cancer progression. In an effort to avoid
possible biases associated with selection of more advanced cases, we examined p53 inactivation in a population-based study of
bladder cancer in New Hampshire, using both mutation and immunohistochemical methods. We found the overall prevalence of
mutation to be approximately 10%, while immunohistochemical analysis suggests that approximately 66% of the tumours have
dysregulated p53 at the protein level. There was a significant association of mutation with persistent p53 staining, but there remained
a marked number of tumours discordant for mutation and aberrant p53 immunohistochemistry. Based upon immunohistochemical
staining alone, intensity rather than extent of p53 staining was more strongly related to tumour invasiveness. Additionally, all tumours
with a mutation in exon 8 stained intensely. Taken together, this suggests that intense staining represents a distinct phenotype of
dysfunctional protein. Our data indicate that population-based approaches to somatic alteration of p53 in bladder cancer are crucial
to understanding the relationship of p53 changes to aetiology and the outcome of this disease, and further suggest that the pattern of
immunohistochemical staining may represent distinct, discernible phenotypes.
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Approximately 60000 new cases of bladder cancer will be
diagnosed in the United States in 2003 (Jemal et al, 2003). This
disease occurs predominantly in Caucasians, with other racial/
ethnic groups having at least a 50% lower incidence. Regardless of
racial or ethnic group, the male-to-female ratio of disease
incidence approaches three to one (Jemal et al, 2003). Bladder
cancer occurs overwhelmingly in one histologic cell type (transi-
tional cell), although squamous cell carcinoma and adenocarcino-
ma of the bladder do occur rarely (Silverman et al, 1996). At the
time of its initial diagnosis, bladder cancers tend to be of lower
stage (Larsson et al, 2003). These noninvasive tumours tend to
have a significantly higher survival rate (Larsson et al, 2003;
Soloway et al, 2003). Yet, many early-stage bladder cancers will
recur and remain superficial and noninvasive for extended
periods, while a minority can become invasive and life threatening.
The factors that are responsible for altering the noninvasive
phenotype of these cancers remain poorly appreciated.
It is clear that inactivation of the p53 pathway is important in
bladder cancer, as the number of tumours having p53 mutations
increases with the degree of invasiveness of the tumour. At the
same time, a large fraction of early-stage disease displays altered
p53 staining, suggesting that the p53 pathway is disrupted in some
fashion. The significance of this discordance is unclear; stabilisa-
tion of nuclear protein could indicate that the protein is mutant,
but might also reflect an altered activation pathway for p53 or
disrupted turnover kinetics. P53 protein in the cell is tightly
regulated, with negligible antibody staining noted in normal
tissues. However, inhibition of degradation, mutation or enhanced
production of p53 protein (or some combination of these) could all
result in antibody recognition of the protein and thus abnormal
staining.
Our understanding of the p53 pathway in bladder cancer derives
largely from hospital-based and retrospective studies that have
captured advanced stage patients undergoing surgery for their
disease (Spruck et al, 1994; Silverman et al, 1996; Smith et al, 2003;
Soloway et al, 2003). Population-based approaches have been used
to avoid possible biases attributable to the study of aggressive and
invasive disease (Berggren et al, 2001; Larsson et al, 2003). Overall,
the prevalence of mutation has varied quite widely, with the larger
and population-based studies tending to report a smaller
prevalence of mutation (Sidransky et al, 1991; Fujimoto et al,
1992; Cordon-Cardo et al, 1994; Berggren et al, 2001). Studies
indicate that the presence of mutation at p53 markedly increases
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ywith stage and grade of disease (Spruck et al, 1994; Berggren et al,
2001; Smith et al, 2003). This has led some to suggest that there
could be a very sharp boundary between the different disease
categories (Larsson et al, 2003). The few studies that compared
both immunohistochemical staining and p53 mutation found
appreciable staining in tumours harbouring mutations, as
expected (Esrig et al, 1993; Cordon-Cardo et al, 1994; Oyasu et al,
1995; Vet et al, 1995; Abdel-Fattah et al, 1998; Bernardini et al,
1999). These studies also observed a surprising number of
discordant samples where p53 immunohistochemistry (IHC) was
positive but no mutation was detectable.
Both the early-stage tumours lacking persistent staining and
those cancers with p53 staining may later undergo p53 mutation
and become aggressive and invasive. Thus, one might expect the
immunohistochemical p53 staining pattern to differ between
tumours with stabilised wild-type p53 protein and those in which
the protein is mutant. To examine the characteristics of positive
staining for p53 protein in bladder tumours systematically, we
evaluated both p53 mutation and immunohistochemical staining
of p53 in a population-based sample of bladder cancers from
inhabitants of New Hampshire. We sought to determine the
associations of p53 mutation with clinical stage and grade of
tumour in the general population setting and elucidate the
relationship of staining characteristics, mutation and the clinical
and pathologic features of the tumours.
MATERIALS AND METHODS
Study population
Residents of New Hampshire aged 25–74 years, diagnostic from
July 1, 1994 to June 30, 1998, were identified by a rapid reporting
system of the New Hampshire State Cancer Registry (Karagas et al,
1998). Briefly, by state law, practitioners are required to provide a
report of cancer patient after diagnosis. Study participants
completed an extensive interview to obtain information on
demographic traits and carcinogen exposure (Karagas et al, 1998).
Pathology reports and paraffin-embedded tumour specimens
were requested from the treating physician/pathology laboratories.
Bladder tumours were reviewed by one pathologist and classified
according to the WHO classification of bladder tumours. DNA was
extracted by a previously reported method (Nelson et al, 1998).
Briefly, three 20-mm sections were cut and transferred into tubes
with digestion buffer. After microwave treatment and centrifuga-
tion, the paraffin ring was removed. Paraffin-free tissue pellets
were suspended in digestion buffer with proteinase K. Super-
natants containing DNA lysate were boiled to denature the residual
protease.
Immunohistochemistry
Immunohistochemical staining of paraffin-embedded slides was
performed using the avidin–biotin complex technique. For each
case, a single representative slide was selected for staining and
histologic evaluation. Briefly, slides were deparaffinised and
hydrated into water. Slides underwent antigen retrieval in Citra
solution using the Biocare Decloaking Chamber (Biocare Medical,
Walnut Creek, CA, USA). Staining of p53 was performed using a
monoclonal antibody (BioGenex, San Ramon, CA, USA) at a 1:100
dilution on the Optimax I-6000 Immunostainer (BioGenex). An
appropriate positive control was used in each staining run, and
each slide was stained with a negative control. The intensity of
nuclear staining was graded on a semiquantitative scale (0–3),
rating intensity in the dominant pattern within the tumour. In
addition, the percentage of positively staining tumour cells was
scored (negative, 1–9%, 10–49%, or X50%).
Mutation analysis
SSCP analysis of p53 exons 5–9 was performed on all bladder
tumour samples. Exons were amplified by PCR containing
fluorescence dye-labelled primers. Previously reported primer
sequences for each exon were used (Toguchida et al, 1992). In all,
1ml of PCR product and 1ml TAMRA-350 size standard (Applied
Biosystems, Foster City, CA, USA) were denatured in 4mlo f
formamide/blue-dextran denaturing buffer at 951C for 5min, and
then loaded onto MDE gels. Gel electrophoresis was carried out on
a DNA autosequencer ABI Prism 377 (Applied Biosystems), with
an external cooling system (Thermo NESLAB Portsmouth, NH,
USA) attached for gels run at 251C. Genescan 3.1 software (Applied
Biosystems) was used for fragment analysis. Samples with variant
SSCP bands were purified using Centri-Sep columns (Princeton
Separations Adelphia, NJ, USA) and directly sequenced by a DNA
autosequencer ABI Prism 377 using the Big Dye Terminator v3.0
sequencing kit (Applied Biosystems) according to the manufac-
turer’s instructions. The data were analysed with the Sequencing
Analysis 3.3 software (Applied Biosystems) and Sequencher 4.1
software (Gene Codes Corporation, Ann Arbor, MI, USA).
Statistical analysis
We examined the prevalence of p53 mutation, persistent staining
(X50%) and strong intensity (3þ) by patient demographic
characteristics and tumour histology and stage. We also used the
disease group classification described by Larsson (Larsson et al,
2003), which distinguished patient survival. We estimated the
prevalence odds ratios (POR) and 95% confidence intervals (CI) of
patient demographic and tumour traits for each p53 mutation,
persistent staining and strong intensity separately, using a log-
linear model with adjustment for the other factors. We also
calculated the sensitivity, specificity and predictive positive values
to evaluate the concordance between p53 mutation and the two
immunohistochemistry parameters (i.e., persistent staining and
strong intensity). We further performed a logistic regression
analysis to contrast those with tumours containing both mutation
and positive immunohistochemistry with tumours that had no
evidence of either a p53 mutation or positive immunohistochem-
istry. Lastly, we compared the number of tumours with intensity
staining and the number of tumours with invasive disease by the
type of p53 mutation using a w
2 test. Due to the sparse numbers of
tumours, we grouped the low-grade tumours (G1 and G2) together
when necessary.
RESULTS
Pathology materials of 421 of 438 (92%) cases were independently
reviewed. Of those re-reviewed, 11 (3%) were deemed non-
cancerous by the study pathologist. In addition to these cases, we
excluded the tumours from a subject who had multiple tumours of
two histologies and tumours from the 15 non-white subjects. Of
the remaining tumours, we performed mutational analysis on 330
tumours, and assessed persistent staining and staining intensity in
356 tumours. There were no significant clinical or demographic
differences comparing those patients included and excluded for
p53 study. The overall prevalence of p53 mutation was 9.1% (30
out of 330; Table 1). There was no statistically significant
difference in mutation prevalence by gender or age, although
there were more mutations in women than men. The prevalence of
p53 mutation increased from 4.6% for the noninvasive low-grade
tumours to 19.4% for the noninvasive high-grade tumours
(POR¼4.4; 95% CI¼1.5–12.5) and to 15.4% for invasive tumours
(POR¼3.4; 95% CI¼1.4–8.0). Likewise, the prevalence of
mutation clearly increased with more advanced disease group
(using the Larsson classification (Larsson et al, 2003)), with a POR
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tumours (Table 1).
The same tumours were evaluated for p53 presence using
immunohistochemical staining, using separate criteria for the
extent of staining (X50% of the cells in the tumour having
evidence of persistent p53 protein) and intensity (scored as 0, 1, 2
or 3). When these data were analysed, we also observed no effect of
gender or age on inactivation of p53 (Table 1). Strong intensity of
staining (3 vs o3) was associated with tumour invasiveness and
grade; 63% (60 out of 96) of the invasive tumours had an intensity
rating of 3, while only 6% (13 out of 218) of the noninvasive
tumours were intensely stained (POR¼10.8; 95% CI¼5.9–19.9).
Again, with the Larsson disease group classification (Larsson et al,
2003), the POR for T2 tumours was increased for intense p53
staining (POR¼12.4; 95% CI¼6.3–24.2) compared to TaG1–G2
tumours. There was a much less marked association of positive
IHC staining with invasive disease when the criteria were based on
the proportion of positively staining cells (X50%) (Table 1).
Table 2 (a) and (b) provides the relationship between the
different measures of p53 alteration. The sensitivity and specificity
were both higher for intense IHC staining than persistent staining
when compared with p53 mutation (Table 2 (a)). Persistent
staining alone was far more prevalent than intense staining,
although there was a significant correlation between the two
measures (Table 2 (b)).
In an effort to refine our estimates of the clinical factors
associated with alterations of the p53 pathway, we compared the
tumours containing both a p53 mutation and evidence of
inactivation by IHC with those that were wild type for IHC and
mutation (Table 3). P53 inactivation clearly increased with tumour
grade (Table 3). Also, the classification of bladder cancers by
disease group indicated a substantial increase in prevalence of
both persistent and intense p53 staining in the presence of
mutation associated with more aggressive disease (Table 3).
We further examined whether the pattern of p53 staining was
related to a part of the p53 gene (i.e. a specific exon). As is evident
in Table 4, all of the mutations in exon 8 were associated with
intense staining. Four of the five tumours with exon 8 mutations
were invasive. Compared with all other exons, there was a
significant association of intense staining with a mutation in exon
8 of the p53 gene (P¼0.02).
DISCUSSION
We used a population-based approach to examine somatic
inactivation of the p53 gene in bladder cancer. We observed the
overall prevalence of p53 mutation to be approximately 10%. This
is similar to that reported by Berggren et al (2001) in a large, non-
hospital-based study in Sweden. Other studies that selected for
hospitalised cases and specifically patients who undergo cystect-
omy report much higher frequencies of p53 mutation (Sidransky
et al, 1991; Fujimoto et al, 1992; Cordon-Cardo et al, 1994). This is
likely attributable to the clear association of p53 mutation with
disease grade and stage. In our study (as well as almost all others),
the prevalence of mutation increases with degree of invasiveness,
and hospitalised patients will certainly be more likely to have more
invasive disease that requires medical intervention. This suggests
that p53 mutations normally occur late in the evolution of bladder
tumours and that they are associated with a rapid, invasive
phenotype.
The significance of the discordance between IHC-positive
tumours and p53 mutation is unclear, although it is commonly
reported (Gao et al, 2000; Babjuk et al, 2002; Doak et al, 2003).
Table 1 Prevalence of p53 mutation, p53 IHC persistent staining (X50%) and p53 IHC strong intensity (3+)
p53 mutation p53 persistent staining p53 strong intensity
N
(prevalence)
Prevalence
OR (95% CI)
a N (prevalence)
Prevalence OR
(95% CI)
a N (prevalence)
Prevalence OR
(95% CI)
a Totals
b
All subjects 30 (9.1) 236 (66.3) 89 (25.0) 356 (100.00)
Gender
Female 10 (13.3) 1.0 (reference) 58 (69.9) 1.0 (reference) 18 (21.7) 1.0 (reference) 83
Male 20 (7.8) 0.6 (0.3–1.2) 178 (65.2) 0.9 (0.7–1.3) 71 (26.0) 0.9 (0.5–1.5) 273
Age
o55 8 (12.3) 1.0 (reference) 47 (67.1) 1.0 (reference) 17 (24.3) 1.0 (reference) 70
55–65 4 (3.7) 0.3 (0.1–1.1) 81 (68.1) 1.0 (0.7–1.5) 31 (26.1) 1.0 (0.6–1.8) 119
465 18 (11.5) 0.9 (0.4–2.1) 108 (64.7) 1.0 (0.7–1.4) 41 (24.6) 0.8 (0.4–1.4) 167
Histology
Transitional cell 29 (8.9) 1.0 (reference) 233 (66.4) 1.0 (reference) 85 (24.2) 1.0 (reference) 351
Nontransitional
cell
1 (20.0) 0.7 (0.1–5.8) 3 (60.0) 1.2 (0.4–3.7) 4 (80.0) 0.9 (0.3–2.5) 5
Stage
Noninvasive, G1–G2 9 (4.6) 1.0 (reference) 150 (68.8) 1.0 (reference) 13 (6.0) 1.0 (reference) 218
Noninvasive, G3 6 (19.4) 4.4 (1.5–12.5) 15 (46.9) 0.7 (0.4–1.2) 8 (25.0) 4.5 (1.8–10.9) 32
In situ 1 (10.0) 2.5 (0.3–21.2) 8 (80.0) 1.2 (0.6–2.5) 8 (80.0) 14.5 (5.8–35.9) 10
Invasive 14 (15.4) 3.4 (1.4–8.0) 63 (65.6) 1.0 (0.7–1.3) 60 (62.5) 10.8 (5.9–19.9) 96
Disease group
c
TaG1-2 9 (4.6) 1.0 (reference) 150 (68.8) 1.0 (reference) 13 (6.0) 1.0 (reference) 218
CIS 1 (10.0) 2.6 (0.3–21.4) 8 (80.0) 1.2 (0.6–2.5) 8 (80.0) 14.7 (5.9–36.4) 10
TaG3/T1 12 (14.3) 3.2 (1.3–7.6) 49 (55.1) 0.8 (0.6–1.1) 40 (44.9) 8.0 (4.2–15.0) 89
T2 8 (21.1) 4.8 (1.8, 12.8) 29 (74.4) 1.1 (0.7–1.7) 28 (71.8) 12.4 (6.3–24.2) 39
aPrevalence ORs adjusted for all other variables in the table except disease group.
bMutation data available on 330 subjects.
cPrevalence ORs adjusted for gender, age and
histology.
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assumed that stabilisation of nuclear protein indicates that the
protein is mutant. However, the presence of wild-type protein may
indicate that p53 is functionally inactive because of alterations in
the pathways that lead to its activation. Candidates for alteration in
this pathway clearly include the MDM2 protein, which is
responsible for catalysing the ubiquitination and degradation of
p53. MDM2 is often altered in bladder cancer (Lu et al, 2002), and
thus should be evaluated in concert with examination of p53 for
persistent and intense staining, as well as with mutation.
Regardless of the mechanism, in the case where the p53 protein
is normal, but persistent staining is detectable, its function is most
likely dramatically altered. It is clearly possible (perhaps even
likely) that tumour clones with mutations in the p53 gene have
features distinct from tumours that have other alterations in the
pathway.
Importantly, our data suggest that the histologic character of
staining (i.e. intensity of staining vs percent) is more indicative of
Table 2 Concordance between: (a) p53 mutation and p53 IHC staining; (b) p53 IHC persistent staining and p53 IHC strong intensity
(a) p53 Mutation
(neg) N (%) (pos) N (%) Total N Specificity Sensitivity
(Pos) (95% CI)
predictive value
(Neg) (95% CI)
predictive value
IHC persistent
(450%)
0.34 (0.29–0.39) 0.77 (0.72–0.81) 0.10 (0.07–0.14) 0.94 (0.91–0.96)
+ (pos) 197 (65.9) 23 (76.7) 220
  (neg) 102 (34.1) 7 (23.3) 109
IHC intensity (3+) 0.77 (0.72–0.82) 0.53 (0.48–0.59) 0.19 (0.15–0.23) 0.94 (0.92–0.97)
+ (pos) 69 (23.1) 16 (53.3) 85
  (neg) 230 (76.9) 14 (46.7) 244
299 (100.0) 236 (100.0) 329 (100.0)
(b) IHC persistent (X50%)
(neg) N (%) (pos) N (%) Total N Specificity Sensitivity (Pos) (95% CI)
predictive value
(Neg) (95% CI)
predictive value
IHC intensity (3+) 0.83 (0.80–0.87) 0.29 (0.25–0.34) 0.78 (0.73–0.82) 0.37 (0.32–0.42)
+ (pos) 20 (16.7) 69 (29.2) 89
  (neg) 100 (83.3) 167 (70.8) 267
120 (100.0) 236 (100.0) 356 (100.0)
Table 3 Concordant p53 mutation and p53 IHC staining by demographic and clinical characteristics
p53 mutation/persistent staining p53 mutation/intensity
p53 wt/IHC o50% p53 mutant/IHC450% OR (95% CI)
a p53 wt/IHC o3 p53 mutant/IHC 3+ OR (95% CI)
a
Characteristic N (%) N (%) N (%) N (%)
Sex
Female 22 (21.6) 9 (39.1) 1.0 (reference) 54 (23.5) 6 (37.5) 1.0 (reference)
Male 80 (78.4) 14 (60.9) 0.5 (0.2–1.6) 176 (76.5) 10 (62.5) 0.4 (0.1–1.4)
Age (year)
o55 18 (17.6) 7 (30.4) 1.0 (reference) 44 (19.1) 4 (25.0) 1.0 (reference)
55–65 34 (33.3) 3 (13.0) 0.2 (0.0–0.9) 78 (33.9) 3 (18.8) 0.4 (0.1–2.2)
465 50 (49.0) 13 (56.5) 0.4 (0.1–1.5) 108 (47.0) 9 (56.2) 0.5 (0.1–2.2)
Stage
Noninvasive 71 (70.3) 10 (43.4) 1.0 (reference) 197 (86.0) 4 (25.0) 1.0 (reference)
Invasive 30 (29.7) 13 (56.5) 1.5 (0.5–4.7) 32 (14.0) 12 (75.0) 3.3 (0.8–13.0)
Grade
G1 25 (24.8) 2 (8.7) 1.0 (reference) 109 (47.6) 0 —
G2 41 (40.6) 4 (17.4) 1.4 (0.2–8.8) 82 (35.8) 2 (12.5) 1.0 (reference)
G3 35 (34.7) 17 (73.9) 6.3 (1.0–38.6) 38 (16.6) 14 (87.5) 9.0 (1.7–47.5)
Disease group
b
TaG1-2 57 (55.9) 6 (26.1) 1.0 (reference) 178 (77.4) 2 (12.5) 1.0 (reference)
CIS 1 (1.0) 0 — 1 (0.4) 0 —
TaG3/T1 36 (35.3) 10 (43.5) 3.1 (0.9–9.9) 42 (18.3) 7 (43.7) 17.6 (3.3–92.9)
T2 8 (7.8) 7 (30.4) 10.6 (2.5–45.5) 9 (3.9) 7 (43.7) 77.4 (13.0–460.1)
aORs are adjusted for all other variables in the table except disease group.
bORs are adjusted for gender and age.
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completely inactivated and the protein becomes more densely
distributed in the nucleus of the cell. At the same time, an
increased number of cells with positive (but less intense) staining
may reflect a distinct form of pathway inactivation where
activation or the protein is altered. Our data are consistent with
this hypothesis in that we found at least some specificity for
mutations; all of the mutations in exon 8 were associated with
intense staining.
Finally, our data further suggest that additional work is
needed to fully understand the underlying reason for the
discordance between p53 protein persistence in early-stage
bladder cancer. It seems clear that multiple mechanisms of
p53 alteration are detected by immunohistochemical staining,
and these differences may be associated with the characteristics
of the bladder tumour. In addition, detection of aberrant
p53 protein (along with proteins in the p53 pathway)
using antibody-mediated methods can likely be made
more sensitive and specific for detecting clinically important
endpoints.
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